Us2.ai

Us2.ai is a medical technology company that has developed an FDA-cleared and CE-marked AI platform for fully automated echocardiography analysis. The company's Echo Copilot platform processes cardiac ultrasound studies from DICOM upload to structured clinical report in seconds with zero clicks, delivering automated measurements, disease detection, and findings. Us2.ai detects cardiac amyloidosis, heart failure, aortic stenosis, and pulmonary hypertension, and supports stress echocardiography and strain imaging. The platform achieves a 70% reduction in reporting time and enables 2 additional echo exams per sonographer per day. Deployed in over 500 hospitals across 28+ countries with over 1 million scans analyzed, Us2.ai integrates with existing PACS, CVIS, and EMR systems and is vendor-neutral across GE, Philips, Siemens, and Canon. The company's research has been published in Nature Communications, The Lancet Digital Health, and JACC. Founded in 2017 and headquartered in Singapore, Us2.ai has raised $19.1M in Series A funding from investors including EDBI, SGInnovate, Partech Partners, Peak XV Partners, IHH Healthcare, and Pappas Capital.